Rapport Therapeutics, Inc. Operating Income
Rapport Therapeutics, Inc. (RAPP) reported Operating Income of -$60.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Rapport Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$60.81M.
- Rapport Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$24.21M.
- Rapport Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$38.51M.
- Rapport Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$29.99M.
- Rapport Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$125.10M.
- Rapport Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$83.06M.
- Rapport Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$36.18M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$60.81M 10-Q · filed 2026-08-05 | -$85.02M 10-Q · filed 2026-08-05 | -$123.53M derived: sum of 3 quarters · filed 2026-08-05 | -$153.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$24.21M 10-Q · filed 2026-05-07 | -$62.72M derived: sum of 2 quarters · filed 2026-05-07 | -$92.71M derived: sum of 3 quarters · filed 2026-05-07 | -$122.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$38.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$68.50M derived: sum of 2 quarters · filed 2026-03-10 | -$97.99M derived: sum of 3 quarters · filed 2026-08-05 | -$125.10M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$29.99M 10-Q · filed 2025-11-06 | -$59.48M derived: sum of 2 quarters · filed 2026-08-05 | -$86.59M 10-Q · filed 2025-11-06 | -$110.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$29.50M 10-Q · filed 2026-08-05 | -$56.60M 10-Q · filed 2026-08-05 | -$80.13M derived: sum of 3 quarters · filed 2026-08-05 | -$101.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$27.11M 10-Q · filed 2026-05-07 | -$50.63M derived: sum of 2 quarters · filed 2026-05-07 | -$72.27M derived: sum of 3 quarters · filed 2026-05-07 | -$93.07M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$23.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$45.16M derived: sum of 2 quarters · filed 2026-03-10 | -$65.96M derived: sum of 3 quarters · filed 2026-03-10 | -$83.06M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$21.64M 10-Q · filed 2025-11-06 | -$42.44M derived: sum of 2 quarters · filed 2025-11-06 | -$59.53M 10-Q · filed 2025-11-06 | -$74.33M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$20.80M 10-Q · filed 2025-08-07 | -$37.89M 10-Q · filed 2025-08-07 | -$52.69M derived: sum of 3 quarters · filed 2025-08-07 | -$62.25M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$17.09M 10-Q · filed 2025-05-08 | -$31.89M derived: sum of 2 quarters · filed 2025-05-08 | -$41.45M derived: sum of 3 quarters · filed 2025-05-08 | -$48.08M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$14.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$24.36M derived: sum of 2 quarters · filed 2025-03-11 | -$30.99M derived: sum of 3 quarters · filed 2025-03-11 | -$36.18M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$9.56M 10-Q · filed 2024-11-07 | -$16.19M derived: sum of 2 quarters · filed 2024-11-07 | -$21.39M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$6.63M 10-Q · filed 2024-08-08 | -$11.82M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |